Cytokines and immunopathogenesis of intraocular posterior segment inflammation

References

• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336.
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844–848.
   Google Scholar
• Forrester JV. Duke-Elder lecture. New concepts on the role of autoimmunity in the pathogenesis of uveitis.Eye. 1992;6:433–441.
   Google Scholar
• Caspi RR, Roberge FG, McAllister CG, El-Saied M, Kuwabara T, Gery I, et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J /mmuno/. 1986;136(3):928–933.
   Google Scholar
• De Smet MD, Dayan M, Nussenblatt RB. A novel method for the determination of T-cell proliferative responses in patients with uveitis. Ocul Immunol Inflamm. 1998;6(3):173–178.
   Google Scholar
• Forrester JV, Stott DI, Hercus KM. Naturally occurring antibodies to bovine and human retinal S antigen: a comparison between uveitis patients and healthy volunteers. Br J Ophthalmol. 1989;73(2):155–159.
   Google Scholar
• Froebel KS, Armstrong SS, Cliffe AM, Urbaniak SJ, Forrester JV. An investigation of the general immune status and specific immune responsiveness to retinal-(S)-antigen in patients with chronic posterior uveitis.Eye.1989;3(3):263–270.
   Google Scholar
• Hirose S, Tanaka T, Nussenblatt RB, Palestine AG, Wiggert B, Redmond TM, et al. Lymphocyte responses to retinal-specific antigens in uveitis patients and healthy subjects. Curr Eye Res. 1988;7(4):393–402.
   PubMed Web of Science ®Google Scholar
• Dick AD. Immune regulation of uveoretinal inflammation. Int Ophthalmol. 1999;30:187–202.
   Google Scholar
• Forrester JV, Liversidge J, Dua HS, Dick A, Harper F, McMenamin PG. Experimental autoimmune uveoretinitis: a model system for immunointervention: a review. Curr Eye Res. 1992;11(Suppl):33–40.
   Google Scholar
• Dick AD, Isaacs JD. Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium. Br J Ophthalmol. 1999;83(1 0:1230–1234.
   Google Scholar
• Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol. 2000; 84(1):107–109.
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001 ;13 (1) : 114–119.
   PubMed Web of Science ®Google Scholar
• Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumour immunity. Trends Immunol. 2002;23(4):210–218.
   Google Scholar
• Todryk SM, Melcher AA, Dalgleish AG, Vile RG. Heat shock proteins refine the danger theory. Immunology. 2000;99(3):334–337.
   Google Scholar
• Granucci F, Andrews DM, Degli-Espoti MA, Ricciardi-Castagnoli. 11–2 mediated adjuvant effect of dendritic cells. Trends Immunol. 2002;23(4):169–171.
   Google Scholar
• Black P. Why is the prevalence of allergy and autoimmunity increasing? Trends Immunol. 2001;22:354–355.
   Google Scholar
• Shanks N, Harbuz MS, Jessop DS, Perks P, Moore PM, Lightman SL. Inflammatory disease as chronic stress. Ann NY Acad Sci. 1998;840: 599–607.
   Google Scholar
• Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394(6696):897–901.
   PubMed Web of Science ®Google Scholar
• Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al. Balancing susceptibility to infection and autoimmunity: a role for leptin. Trends Immunol. 2002;23(4):162–187.
   Google Scholar
• Caspi RR, Grubbs BG, Chan CC, Chader GJ, Wiggert B. Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes. J Immunol. 1992;148(8):2384–2389.
   Google Scholar
• Davey MP, Rosenbaum JT. The human leukocyte antigen complex and chronic ocular inflammatory disorders. Am J Ophthalmol. 2000;129(2):235–243.
   Google Scholar
• Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease. Tissue Antigens. 1999;54(3): 264–272.
   PubMedGoogle Scholar
• Seki N, Yamaguchi K, Yamada A, Kamizono S, Sugita S, Taguchi C, et al. Polymorphism of the 50-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. J Infect Dis. 1999;180(3):880–883.
   Google Scholar
• Dick AD. Immune mechanisms of uveitis: insights into disease pathogenesis and treatment. Int Ophthalmol Clin. 2000;40(2):1–18.
   Google Scholar
• Nussenblatt RB, Gery I, Weiner HL, Ferris FL, Shiloach J, Remaley N, et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997;123(5):583–592.
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD. CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci. 2001;42(6):1285–1292.
   PubMed Web of Science ®Google Scholar
• Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet's disease. Invest Ophthalmol Vis Sci. 1998;39(6):996–1004.
   Google Scholar
• Arocker-Mettinger E, Asenbauer T, Ulbrich S, Grabner G. Serum interleukin 2-receptor levels in uveitis. Curr Eye Res. 1990;9(Suppl): 25–29.
   Google Scholar
• Scheinberg MA, Ikejiri M, Silva MH, Mota IM. Interleukin 2 receptor membrane bound and in soluble form in the aqueous humor and peripheral blood of patients with acute untreated uveitis. J Rheumato/.1992;19(9):1362–1363.
   Google Scholar
• Whitcup SM, Vistica BP, Magone MT, George RK. Elevated serum levels of soluble ICAM-1 in uveitis patients predict underlying systemic disease. Br J Ophthalmol. 1 9 9 9 ; 83(2):252–253.
   Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173.
   PubMed Web of Science ®Google Scholar
• Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193(11): 1303–1310.
   Google Scholar
• Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 2001;3(10:947–954.
   Google Scholar
• Read S, Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol. 2001;13(6):644–649.
   Google Scholar
• Rhodes SG, Palmer N, Graham S P, Bianco AE, Hewinson RG, Vordermeier HM. Distinct response kinetics of gamma interferon and interleukin-4 in bovine tuberculosis. Infect Immun.2000;68(9):5393–5400.
   Google Scholar
• Rhodes SG, Graham SP. Is 'timing' important for cytokine polarisation. Trends Immunol. 2002;23(5): 246–249.
   Google Scholar
• Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. IFNg production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 200 1; 22(10):556–560.
   Google Scholar
• Forrester JV, Huitinga I, Lumsden L, Dijkstra CD. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res. 1998;17(4):426–437.
   PubMed Web of Science ®Google Scholar
• Caspi RR, Chan CC, Fujino Y, Najafian F, Grover S, Hansen CT, et al. Recruitment of antigen-nonspecific cells plays a pivotal role in the pathogenesis of a T cell-mediated organ-specific autoimmune disease, experimental autoimmune uveoretinitis. J Neuroiininunol. 1993;47(2):177–188.
   Google Scholar
• Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV, et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol. 1996;26(5): 1018–1025.
   PubMed Web of Science ®Google Scholar
• Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun. 1 9 9 8; 11(3):255–264.
   Google Scholar
• Smith JR, Hart PH, Coster DJ, Williams KA. Mice deficient in tumor necrosis factor receptors p5 5 and p 75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthahnol Vis Sci. 1998;39(3): 658–661.
   Google Scholar
• Higuchi M, Diamantstein T, Osawa H, Caspi RR. Combined anti-interleukin-2 receptor and low-dose cyclosporine therapy in experimental autoimmune uveoretinitis. J Autoimmun. 1 99 1; 4(1):113–124.
   Google Scholar
• Matthys P, Vermeire K, Alfons B. Mac-1+ myelopoiesis induced by CFA: a clue to the paradoxical effects of IFN-g in autoimmune disease models. Trends Immunol. 2001;22(7):367–371.
   Google Scholar
• Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, et al. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol. 1997;158(12):5997–6005.
   PubMed Web of Science ®Google Scholar
• Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol. 1996;26(7):1641–1646.
   PubMed Web of Science ®Google Scholar
• Caspi RR. IL-12 in autoimmunity. Clin Immunol Immunopathol. 1 99 8; 88(1):4–13.
   Google Scholar
• Tarrant TK, Silver PB, Wahlsten JL, Rizzo LV, Chan CC, Wiggert B, et al. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J Exp Med. 1999;189(2):219–230.
   Google Scholar
• Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med. 1990;172(4):1193–1200.
   PubMed Web of Science ®Google Scholar
• Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997;185(9):1573–1584.
   Google Scholar
• Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001;15(4):533–543.
   Google Scholar
• Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology.1987;37(7):1097–1102.
   Google Scholar
• Liversidge J, Dick A, Gordon S. Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis. Am J Pathol. 2002;160(3):905–916.
   Google Scholar
• Silver PB, Tarrant TK, Chan CC, Wiggert B, Caspi RR. Mice deficient in inducible nitric oxide synthase are susceptible to experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 1999;40(6): 1280–1284.
   Google Scholar
• Dick AD, Ford AL, Forrester JV, Sedgwick JD. Flow cytometric identification of a minority population of MHC class II-positive cells in the normal rat retina distinct from CD4510wCD11b/c+CD410w parenchymal microglia. Br J Ophthalmol. 1995;79:834–840.
   PubMedGoogle Scholar
• Ford AL, Foulcher E, Lemckert FA, Sedgwick JD. Microglia induce CD4 T lymphocyte final effector function and death. J Immunol. 1996;184: 1737-1745.
   Google Scholar
• Broderick C, Duncan L, Taylor N, Dick AD. IFN-gamma and LPS mediated IL-10-dependent suppression of retinal microglial activation. Invest Ophthalmol Vis Sci. 2000;41:2613–2622.
   PubMed Web of Science ®Google Scholar
• Jiang HR, Lumsden L, Forrester JV. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci. 1999;40(13):3177–3185.
   Google Scholar
• Dick AD, Broderick C, Forrester JV, Wright GJ. Distribution of 0X2 antigen and 0X2 receptor within retina. Invest Ophthalmol Vis Sci. 2001;42(0:170–176.
   Google Scholar
• Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol. 1998;161(4):1983–1988.
   Google Scholar
• Erwig LP, Rees AJ. Macrophage activation and programming and its role for macrophage function in glomerular inflammation. Kidney Blood Press Res. 1999;22 (1-2): 21–25 .
   Google Scholar
• Robertson MJ, Erwig LP, Liversidge J, Forrester JV, Rees AJ, Dick AD. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Invest Ophthalmol Vis Sci. 2002;43(7): 2250–2257.
   PubMed Web of Science ®Google Scholar
• Crane IJ, Kuppner MC, McKillop-Smith S, Wallace CA, Forrester JV. Cytokine regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) production by human retinal pigment epithelial cells. Clin Exp Immunol. 1999 ; 115(2):288–293.
   Google Scholar
• Crane IJ, Wallace CA, Forrester JV. Regulation of granulocyte-macrophage colony-stimulating factor in human retinal pigment epithelial cells by IL-lbeta and IFN-gamma. Cell Immunol. 2001;209(2): 132–139.
   Google Scholar
• Forrester JV, Liversidge J, Dick A, McMenamin P, Kuppner M, Crane I, et al. What determines the site of inflammation in uveitis and chorioretinitis? Eye. 1997;11(2): 162–166.
   Google Scholar
• Elliott MJ, Maini RN. Anti-cytokine therapy in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995; 9(4) : 633–652.
   Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105–1110.
   PubMed Web of Science ®Google Scholar
• Kruithof E, Kestelyn P. Elewaut C, Elewaut D, Van Den Bosch F, Mielants H, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis. 2002;61(5):470.
   Google Scholar
• Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum.2001;45(3):252–257.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van Veldhuisen P, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 1999;96(13):7462–7466.
   Google Scholar
• Guex-Crosier Y, Raber J, Chan CC, Kriete MS, Benichou J, Pilson RS, et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 1997;158(1):452–458.
   Google Scholar